Skip to main content

Table 1 Characteristic of participants

From: Effects of autologous serum on TREM2 and APOE in a personalized monocyte-derived macrophage assay of late-onset Alzheimer’s patients

 

AD (n = 21)

CO (n = 16)

p-value

Age

72.76 (7.61)

74.93 (6.56)

0.654

BMI (kg/m2)

22.85 (3.73)

22.08(2.8)

0.673

Gender (m/f)

10/11

5/11

 > 0.999

APOE ε4 status (pos. /neg.)

10/11

6/10

 > 0.999

MMSE score

24.13 (3.45)

27.94 (2.51)

0.0004

CSF Aβ1–42

455 (239.13)

952.19 (375.2)

 < 0.0001

CSF Aβ1-42 /Aβ1–40

0.048 (0.021)

0.091 (0.02)

 < 0.0001

CSF – p-tau181

114.82 (52.98)

39.45 (10.94)

 < 0.0001

CSF – t-tau

699.32 (274.52)

279.69 (79.23)

 < 0.0001

  1. Data are shown as mean and standard deviation (SD) unless otherwise stated. AD Alzheimer´s disease, CO Control, APOE Apolipoprotein, CSF Cerebrospinal fluid, Aβ Amyloid β peptide, MMSE Mini-mental state examination, P-tau181 tau phosphorylated at threonine 181, Tau-total tau. Probability values (p) denote differences between groups. Fisher's Exact Tests performed to compare gender and APOEε4 differences between groups. Pairwise comparison of groups was performed with Mann Whitney tests (unpaired groups)